STOCK TITAN

Weed Stock Price, News & Analysis

BUDZ OTC

Welcome to our dedicated page for Weed news (Ticker: BUDZ), a resource for investors and traders seeking the latest updates and insights on Weed stock.

undefined (BUDZ) is a global cannabis bioresearch innovator advancing therapeutic applications through clinical trials and rare strain development. This page provides essential updates on corporate milestones, regulatory compliance, and market strategies shaping the cannabis industry.

Access real-time announcements about clinical research progress, international expansion efforts, and consumer product launches. Users will find verified information on earnings reports, strategic partnerships, and quality assurance protocols that meet rigorous scientific standards.

Content spans regulatory filings, research publications, executive leadership updates, and patent developments. All materials are curated to support informed analysis of BUDZ's unique position at the intersection of biotechnology and cannabis commercialization.

Bookmark this resource for consolidated access to official updates from undefined (BUDZ), ensuring you remain informed about developments in cannabinoid research and global market strategies.

Rhea-AI Summary

WEED Inc. (BUDZ) announced a strategic partnership with Remergify to design, develop, program, deploy and coordinate the launch of WEEDCoin (B2C) and BUDZCoin (B2B) targeting banking and cash-handling challenges in the regulated cannabis and hemp markets.

Key disclosed facts: Remergify will provide blockchain, tokenization and AI expertise; WEED highlights a seedbank of >200 rare strains and says the seedbank has a multi-million-dollar estimated valuation; WEED lists a 44-acre Lake Erie property for sale at $2.1 million; company reports no long-term debt, ~147M shares outstanding with ~34M float, and renewal of five Arizona hemp licenses through end of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
partnership AI
-
Rhea-AI Summary

WEED Inc. (OTCQB: BUDZ) has released its 2024 highlights and 2025 plans. The company plans to expand into consumer packaged goods using rare Landrace cannabis strains. Key 2024 developments include: attendance at the Pharmaceutical Guild of Australia conference, deregistration of Cannabis Institute of Australia and WEED Hong Kong for cost reduction, and securing trademark registrations for 'Panama Red' and 'WEED' in USA and Canada. The company maintains five HEMP licenses in Arizona and is exploring THC grow licensing. WEED Inc. reports having no long-term debt, has never taken convertible notes, and has approximately 125 million shares outstanding with ~31 million shares in float through 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.18%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.52%
Tags
none
Rhea-AI Summary

WEED, Inc. (OTCQB: BUDZ) announced the acquisition of Hempirical Genetics, LLC for 2 million shares valued at $.25 per share and $250,000 in cash over four years. This strategic move, described as a 'game changer', enhances WEED's cannabis genetics programs with over 30 new CBD and CBG strains, ultimately aimed at product development and clinical trials. Jeffery Miller, the previous owner, will lead development at HEMP BioSciences. The company aims to innovate in medical cannabis and build a pipeline of effective products while addressing legal and market uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

WEED, Inc. (OTCQB:BUDZ) announced that WEED Australia Ltd. will attend the United in Compassion Australian Medicinal Cannabis Symposium from May 20-22, 2022, in Queensland. The event aims to enhance understanding of cannabis applications in medicine. Key representatives include CEO Glenn E. Martin and Managing Director Patrick Brodnik. Discussions will focus on potential partnerships and the evolving legal framework for medicinal cannabis in Australia, as more patients seek access. The company aims to lead cannabis research and product development in the Asia-Pacific region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
-
Rhea-AI Summary

WEED, Inc. (OTCQB:BUDZ) announced that its subsidiary, WEED Australia Ltd., has completed its financial statement requirements under ASIC rules, paving the way for a formal public offering anticipated in 2022 or 2023. The company is seeking strategic partnerships to bolster development, with a focus on cannabis-derived compounds for medical applications. CEO Glenn E. Martin will attend the 'United in Compassion' conference in May 2022 to explore collaborative opportunities. Despite positive developments, investors are cautioned about the significant legal risks associated with cannabis operations in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
none
Rhea-AI Summary

WEED, Inc. (OTCQB:BUDZ) announces its strategic focus on expanding its trademark portfolio in the cannabis industry, aiming for enhanced brand recognition and shareholder value. The company holds a registered WEED® trademark and is pursuing additional registrations for PANAMA RED™ and ACAPULCO GOLD™ across various products and services. Through these efforts, WEED, Inc. plans to solidify its position as a leader in the cannabis sector while actively engaging in healthcare innovations for both humans and pets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none

FAQ

What is the current stock price of Weed (BUDZ)?

The current stock price of Weed (BUDZ) is $0.05383 as of January 8, 2026.

What is the market cap of Weed (BUDZ)?

The market cap of Weed (BUDZ) is approximately 4.1M.
Weed

OTC:BUDZ

BUDZ Rankings

BUDZ Stock Data

4.08M
66.54M
51.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Tucson